{'fraction_non_alphanumeric': 0.04900459418070444, 'fraction_numerical': 0.022970903522205207, 'mean_word_length': 3.9923664122137406, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Novo Nordisk v.. Caraco: Who defines the use code narrative?

In Novo Nordisk A/S et al. v. Caraco Pharma. Labs., Ltd. et al., 688 F.3d 766 (Fed. Cir. 2012), the Federal Circuit addressed the scope of the injunction issued by the District Court in light of the Supreme Court's decision in Caraco Pharmaceutical Laboratories Ltd. et al. v. Novo Nordisk A/S et al. (U.S. 2012). The Federal Circuit found that the District Court had abused its discretion in issuing its injunction and modified the injunction accordingly. This case report presents the arguments made to the Federal Circuit by the parties and how the Federal Circuit addressed those issues.